It has been known for decades that degeneration of the locus coeruleus (LC), the major noradrenergic nucleus in the brain, occurs in both Alzheimer's disease (AD) and Parkinson's disease (PD), but it was given scant attention. It is now recognized that hyperphosphorylated tau in the LC is the first detectable AD-like neuropathology in the human brain, a-synuclein inclusions in the LC represent an early step in PD, and experimental LC lesions exacerbate neuropathology and cognitive/behavioral deficits in animal models. The purpose of this review is to consider the causes and consequences of LC pathology, dysfunction, and degeneration, as well as their implications for early detection and treatment.
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Locus Coeruleus Degeneration in Alzheimer's Disease and Parkinson's Disease
Alzheimer's disease (AD) and Parkinson's disease (PD) are the two most prevalent neurodegenerative diseases. While their primary symptoms are distinct (memory loss in AD, motor symptoms in PD), both are characterized by protein aggregates (b-amyloid plaques and tau neurofibrillary tangles in AD, a-synuclein Lewy bodies in PD), and they share comorbid symptoms such as depression, anxiety, sleep abnormalities, and cognitive impairment. An underappreciated hallmark of both diseases is the degeneration of the brainstem locus coeruleus (LC), the major norepinephrine (NE)-producing nucleus in the brain [1] [2] [3] [4] [5] . Given the importance of the LC for the regulation of attention, arousal, and mood [6, 7] , a potential role for LC degeneration has been suggested for certain neuropsychiatric abnormalities that are common in both AD and PD, such as anxiety, depression, and sleep disorders [8] [9] [10] [11] .
LC cell loss was first described in AD and PD more than 30 years ago [12, 13] . Although nearly ubiquitous and profound ($50-80%), it was largely ignored in favor of other neurotransmitter systems/nuclei, even though the extent of LC/NE degeneration surpasses even nucleus basalis/acetylcholine loss in AD and dopamine (DA)/substantia nigra loss in PD [14] . The neurodegeneration field has recently taken notice of the LC for two reasons. First, we and others have shown that LC lesions exacerbate AD-and PD-like neuropathology and cognitive/ behavioral deficits in animal models [1, [15] [16] [17] [18] [19] [20] [21] [22] . Second, evidence from postmortem studies indicates that some of the primary AD (tau) and PD (a-synuclein) pathologies appear very early in the LC. For example, hyperphosphorylated tau, a 'pretangle' form of the protein that is prone to aggregation, can be detected in the LC before anywhere else in the brain, sometimes during the first few decades of life [5, [23] [24] [25] [26] [27] [28] . Likewise, a-synuclein pathology appears in LC neurons before infiltrating the substantia nigra pars compacta, the canonical midbrain dopaminergic nucleus that controls motor function [29] [30] [31] [32] . These LC pathologies often precede the primary symptoms of each disorder (dementia in AD, motor dysfunction in PD), suggesting that LC loss may contribute to disease initiation, progression, and severity rather than merely representing collateral damage in a dying brain [33] . Importantly, normal aging does not affect the LC,
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A unique combination of neuroanatomy, neurochemistry, and physiology render LC neurons vulnerable to insults and degeneration.
The LC is among the earliest sites of detectable pathology in AD (tau) and PD (a-synuclein), and may seed the development of aberrant protein aggregates in interconnected brain regions.
In both AD and PD, LC neurons display dysfunction, fiber degeneration, and cell death.
LC dysfunction and degeneration likely contribute to neuropsychiatric, neurological, and cognitive symptoms in AD and PD.
